High impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·Effective Sep 24, 2026
Arkansas Blue Cross updated authorization renewal criteria for 8 oncology and specialty pharmaceutical drugs, effective September 24, 2026. Changes simplify renewal requirements to focus on disease stability/improvement, manageable side effects, and specific treatment parameters (e.g., no therapeutic duplication for Panitumumab, 24-month treatment limit for Retifanlimab-dlwr). Additionally, the legacy Chemotherapy for Malignancy policy (2000030) will be archived on October 24, 2026, with replacement coverage under new policy 2026011.